Bausch Health Companies (NYSE:BHC) - Prezzo delle azioni, notizie e analisi

BHC Panoramica delle azioni

Bausch Health Companies Inc. opera come azienda diversificata di specialità farmaceutiche e dispositivi medici negli Stati Uniti e a livello internazionale. Maggiori dettagli

BHC analisi fondamentale
Punteggio fiocco di neve
Valutazione	5/6
Crescita futura	3/6
Prestazioni passate	0/6
Salute finanziaria	2/6
Dividendi	0/6

Premi

Negoziato a 83.9% al di sotto della nostra stima del suo valore equo

Si prevede che gli utili cresceranno del 218.28% all'anno

Gli utili sono cresciuti del 34.6% all'anno negli ultimi 5 anni

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Patrimonio netto negativo

Bausch Health Companies Inc. Concorrenti

Perrigo

NYSE:PRGO

US$3.8b

Amneal Pharmaceuticals

NasdaqGS:AMRX

US$2.6b

Organon

NYSE:OGN

US$3.9b

Prestige Consumer Healthcare

NYSE:PBH

US$4.2b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Bausch Health Companies
Prezzi storici delle azioni
Prezzo attuale dell'azione	US$7.97
Massimo di 52 settimane	US$11.46
Minimo di 52 settimane	US$3.96
Beta	0.74
1Variazione di 1 mese	-0.87%
Variazione a 3 mesi	33.50%
Variazione di 1 anno	15.01%
3Variazione a 3 anni	-68.44%
Variazione a 5 anni	-71.78%
Variazione dall'IPO	1,494.00%

Notizie e aggiornamenti recenti

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Oct 10

Recent updates

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Oct 10

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Sep 19

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Aug 06

2 Red Alerts On Bausch Health Companies

Jul 25

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

May 21

Bausch Health Companies (NYSE:BHC) Strong Profits May Be Masking Some Underlying Issues

Nov 10

Bausch Health Companies Q3 2022 Earnings Preview

Nov 02

Rendimenti per gli azionisti

	BHC	US Pharmaceuticals	US Mercato
7D	-6.0%	1.6%	2.2%
1Y	15.0%	9.9%	31.6%

Ritorno vs Industria: BHC ha superato il US Pharmaceuticals che ha restituito 9.9 % nell'ultimo anno.

Rendimento vs Mercato: BHC ha avuto una performance inferiore al mercato US che ha registrato un rendimento 31.6 % nell'ultimo anno.

Volatilità dei prezzi

Is BHC's price volatile compared to industry and market?
BHC volatility
BHC Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	9.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	3.1%

Prezzo delle azioni stabile: BHC non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 7% ) di BHC è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. opera come azienda diversificata di specialità farmaceutiche e dispositivi medici negli Stati Uniti e a livello internazionale. Sviluppa, produce e commercializza una serie di prodotti principalmente in gastroenterologia, epatologia, neurologia, dermatologia, prodotti farmaceutici internazionali, prodotti da banco (OTC), dispositivi medici estetici e salute degli occhi. L'azienda opera attraverso cinque segmenti: Salix, International, Solta Medical, Diversified e Bausch + Lomb.

Bausch Health Companies Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Bausch Health Companies con la sua capitalizzazione di mercato?
BHC statistiche fondamentali
Capitalizzazione di mercato	US$2.93b
Guadagni(TTM)	-US$178.00m
Ricavi(TTM)	US$9.47b

0.3x

Rapporto P/S

-16.5x

Rapporto P/E

BHC è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
BHC Conto economico (TTM)
Ricavi	US$9.47b
Costo del fatturato	US$2.76b
Profitto lordo	US$6.71b
Altre spese	US$6.89b
Guadagni	-US$178.00m

Ultimi guadagni dichiarati

Sep 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	-0.48
Margine lordo	70.87%
Margine di profitto netto	-1.88%
Rapporto debito/patrimonio netto	-8,887.2%

Come si è comportato BHC nel lungo periodo?

Vedi performance storica e confronto

BHC Panoramica delle azioni

Premi

Analisi del rischio

Bausch Health Companies Inc. Concorrenti

NYSE:PRGO

US$3.8b

NasdaqGS:AMRX

US$2.6b

NYSE:OGN

US$3.9b

NYSE:PBH

US$4.2b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Price target increased by 7.1% to US$8.57

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

There's No Escaping Bausch Health Companies Inc.'s (NYSE:BHC) Muted Revenues Despite A 28% Share Price Rise

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Sale Rumors Lift Both Bausch + Lomb And Parent Bausch Health - A Breakthrough Is Likely

Price target decreased by 18% to US$7.79

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Executive VP & General Counsel exercised options and sold US$318k worth of stock

Investors Don't See Light At End Of Bausch Health Companies Inc.'s (NYSE:BHC) Tunnel And Push Stock Down 28%

Price target decreased by 11% to US$8.36

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

2 Red Alerts On Bausch Health Companies

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Price target decreased by 7.7% to US$9.56

The Market Doesn't Like What It Sees From Bausch Health Companies Inc.'s (NYSE:BHC) Revenues Yet As Shares Tumble 25%

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

Why Bausch Health Stock Plunged After Posting First-Quarter 2024 Results

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Price target increased by 10% to US$10.33

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Bausch Health: A Timely Divestiture Is The Key To An Higher Valuation

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall from profit to US$0.03 loss

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Bausch Health: $20bn Debt Is A Mighty Elephant In The Room

Consensus EPS estimates fall by 89%, revenue upgraded

New major risk - Negative shareholders equity

No longer forecast to breakeven

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Does Bausch Health Companies (NYSE:BHC) Have A Healthy Balance Sheet?

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Consensus EPS estimates fall by 31%

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Consensus EPS estimates fall from profit to US$0.49 loss

Bausch Health's Debt Dilemma: Strategic Decisions And Financial Metrics

Price target increased by 11% to US$9.50

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Executive VP & CFO exercised options to buy US$1.1m worth of stock.

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Consensus EPS estimates increase from loss to US$0.11 profit

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)